Montreux Equity Partners
Venture capitalSan Francisco · Growth–Late Stage · 3 people tracked
Also known as Montreux Equity Partners Associates IIIB
Find your way into Montreux Equity Partners
1 people in our graph share verified history with the Montreux Equity Partners team — schools, employers, funds. One of them is your warm intro.
Investment thesis
The firm invests growth capital in category-leading, commercial-stage companies in healthcare and financial technology. Target companies typically have highly differentiated products, technologies, or services and $5 to $50 million in annual revenue at the time of investment. Individual checks generally range from $10 to $20 million, with capital used to fuel product expansion and innovation, new market entry, and strategic acquisitions. A cohesive team collaborates across diligence, investment decisions, and portfolio management, bringing complementary operational, financial, and sector expertise to actively support portfolio companies.
Source: firm website, verified Sep 5, 2026.
Team · 3 people
from public directoriesWhat they invest in
from 4 of 5 portfolio companiesHealthtech ×4Medical Devices ×2AI & Machine Learning ×1Biotech ×1Digital Health ×1SaaS ×1
HQs:United States×3
Investments · 5 tracked
founders shown can be your intro path
Pulmonx develops the Zephyr Valve, a bronchoscopic device used to treat patients with severe COPD/emphysema without surgery.
BiotechHealthtechMedical DevicesSan Jose, US
LAUREN CRISTINA(Executive Officer)inSri Radhakrishnan(Chief Technology Officer)inMICHAEL BAKER(Executive Officer, Director)inGlendon E. French(Chief Executive Officer and Director)Derrick Sung(Chief Operating Officer and Chief Financial Officer)inGeoffrey Beran Rose(Chief Commercial Officer)
Co-investorsBand of AngelsHealthCapKaiser Permanente VenturesLatterell Venture PartnersAlly Bridge Group
SI-BONE develops medical devices for treating sacroiliac (SI) joint dysfunction and chronic low back pain, targeting patients and physicians.
HealthtechMedical DevicesSan Jose, US
Mark Reiley(Director)inJeffrey W. Dunn(Executive Officer, Director)Robert E. Johnson(Executive Officer)Dan Murray(Executive Officer)Laura A. Francis(Chief Executive Officer)
BoardTimothy E. Davis(Director)
Co-investorsArboretum VenturesOrbiMed
TigerConnect provides a clinical communication and collaboration platform for hospitals and healthcare organizations, offering HIPAA-compliant messaging, scheduling, patient transfer, and AI-driven workflow tools.
AI & Machine LearningDigital HealthHealthtechSaaS
Brad Brooks(Co-Founder & Executive Chairman)inAndrew Brooks(Co-Founder & Chief Medical Officer)inSean O'Neal(CEO)inTim Goodwin(Chief Technology Officer)inSheeza Hussain(Chief Growth Officer)inBrian Kaminski(Chief Customer Officer)in
Co-investorsVista Equity PartnersCorewell Health VenturesNew Science VenturesNorwest Venture PartnersOrbiMedShasta Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Adigica HealthTebra
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
2 IPOsPulmonx Corp.NASDAQ: LUNGSI-BONENASDAQ: SIBN
Portfolio news
latest coverage across their companiesSI-BONE · biospace.com · Aug 4, 2026
Pulmonx Corp. · defenseworld.net · Jul 19, 2026
IPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| SI-BONE | 8.8% | $15.00 | Oct 2018 | $30.4M |
| Pulmonx Corp. | 4.8% | $19.00 | Oct 2020 | $27.2M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Nov 2018
Disclosed stake · filed Nov 2018
Disclosed stake · filed Mar 2018
7 insider ownership filings (Forms 3/4/5)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Montreux Equity Partners made?
- Montreux Equity Partners has 5 tracked investments, 2 of which have exited.
- What stage does Montreux Equity Partners invest at?
- Montreux Equity Partners invests at the Growth, Late Stage stages.
- What is Montreux Equity Partners's typical check size?
- Montreux Equity Partners typically writes checks of $10M – $20M.
- What sectors does Montreux Equity Partners focus on?
- Montreux Equity Partners focuses on Biotech, Digital Health, Fintech, Healthtech, Medical Devices.
- Where is Montreux Equity Partners located?
- Montreux Equity Partners is headquartered in San Francisco, US.
- Who does Montreux Equity Partners co-invest with?
- Montreux Equity Partners most often shares deals with New Science Ventures, Norwest Venture Partners, OrbiMed, among 6 tracked co-investors.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.